Obstacles to the Elimination of Haemophilus influenzae Type b Disease: Three Illustrative Cases [13]

Pediatrics

Volumn 112, Issue 6 I, 2003, Pages 1465-1466

  Donnelly, Michael J ^a   Herold, Betsy C ^a   Jenkins, Steven G ^a   Daum, Robert S ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CEFPODOXIME; CEFTRIAXONE; GENTAMICIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE;

BACTERIAL INFECTION; BLOOD CULTURE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; INFANT; INFECTION PREVENTION; LETTER; MALE; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; TREATMENT OUTCOME; VACCINATION;

BACTEREMIA; CHILD, PRESCHOOL; CLUSTER ANALYSIS; FEMALE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEW YORK; TREATMENT FAILURE; VACCINATION;

EID: 0348111433     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.112.6.1465     Document Type: Letter

References (10)

1. Centers for Disease Control and Prevention. Progress toward elimination of Haemophilus influenzae type b disease among infants and children: United States, 1987-95. MMWR Morb Mortal Wkly Rep. 1996;45:901-906
2. Institute of Medicine. Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality. Washington, DC: National Academy Press; 1994:250-273
3. Daum RS, Siber GR, Ballanco GA, Sood SK. Serum anticapsular antibody response in the first week after immunization of adults and infants with the Haemophilus influenzae type b-Neisseria meningitidis outer membrane protein complex conjugate vaccine. J Infect Dis. 1991:1154-1159
4. Jafari HS, Adams WG, Robinson KA, Plikaytis BD, Wenger JD. Efficacy of Haemophilus influenzae type b conjugate vaccines and persistence of disease in disadvantaged populations. Am J Public Health. 1999;89:364-368
5. Centers for Disease Control and Prevention. Progress toward elimination of Haemophilus influenzae type b disease among infants and children: United States, 1998-2000. MMWR Morb Mortal Weekly Rep. 2002;51:234-237
6. Heath P, Booy R, Azzopardi H, et al. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA. 2000;284:2334-2340
7. Holmes S, Lucas A, Osterholm M, Froeschle JE, Granoff DM. Immunoglobulin deficiency and idiotype expression in children developing Haemophilus influenzae type b disease after vaccination with conjugate vaccine. JAMA. 1991;266:1960-1965
8. Mendoza JC, Roberts JL. Early-onset Hemophilus influenzae sepsis in the neonate. J Perinatol. 1991;11:126-129
9. National, state, and urban area vaccination coverage levels among children aged 19-35 months-United States, 1998. MMWR Morb Mortal Wkly Rep. 2000;49:1-26
10. Singleton R, Bulkow R, Levine OS, Butler JC, Hennessey TW, Parkinson A. Experience with the prevention of invasive Haemophilus influenzae type b disease by vaccination in Alaska: the impact of persistent oropharyngeal carriage. J Pediatr. 2000;137:295-298